Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer
Open accessPublished version of a preprint
The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Mechanisms of acquired resistance to immune checkpoint inhibitors (ICI) are poorly understood. We leveraged a collection of 14 ICI-resistant lung cancer samples to investigate whether alterations in genes encoding HLA Class I antigen processing and presentation machinery (APM) components or interferon signaling play a role in acquired resistance to PD-1 or PD-L1 antagonistic antibodies. Recurrent mutations or copy-number changes were not detected in our cohort. In one case, we found acquired homozygous loss of B2M that caused lack of cell-surface HLA Class I expression in the tumor and a matched patient-derived xenograft (PDX). Downregulation of B2M was also found in two additional PDXs established from ICI-resistant tumors. CRISPR-mediated knockout of B2m in an immunocompetent lung cancer mouse model conferred resistance to PD-1 blockade in vivo, proving its role in resistance to ICIs. These results indicate that HLA Class I APM disruption can mediate escape from ICIs in lung cancer. Significance: As programmed death 1 axis inhibitors are becoming more established in standard treatment algorithms for diverse malignancies, acquired resistance to these therapies is increasingly being encountered. Here, we found that defective antigen processing and presentation can serve as a mechanism of such resistance in lung cancer. Cancer Discov; 7(12); 1420–35. ©2017 AACR. This article is highlighted in the In This Issue feature, p. 1355
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Similar disruptions in MHC I presentation in patients with lung cancer were also reported, implicating dysregulated antigen presentation as a potent mediator of acquired resistance (111).”
From Immune Checkpoint Inhibitors for the Treatment of Cancer: Clinical Impact and Mechanisms of Response and Resistance (2021) · cites this paper as [111]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106 · cited 2×
“Love MI, Huber W, Anders S. Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2.”
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
HTSeq—a Python framework to work with high-throughput sequencing data
Anders, S., Pyl, P. T., & Huber, W. (2015) · Bioinformatics · doi:10.1093/bioinformatics/btu638 · Cited by 21,464
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089 · cited 2×
“In NSCLC, tumors with nondetectable PD-L1 expression are also less responsive to these agents although there is variability depending on the biomarker used (6,8,10).”
BackgroundSignatures of mutational processes in human cancer
Initiative, A. P. C. G., Alexandrov, L. B., ICGC Breast Cancer Consortium, ICGC MMML-Seq Consortium, PedBrain, I., Nik-Zainal, S., Wedge, D. C., Aparicio, S. A. J. R., Behjati, S., Biankin, A. V., et al. (2013) · Nature · doi:10.1038/nature12477 · Cited by 9,660 · cited 2×
“The hypermutator case identified in our cohort (case #17), exhibited a mutation signature rich in C>T transitions suggestive of exposure to an alkylating agent (26).”
BackgroundNivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335 · cited 2×
“The PD-1 axis blockers nivolumab (anti-PD-1) and atezolizumab (anti PD-L1) are additionally indicated for use as second-line therapy in patients with NSCLC regardless of tumor PD-L1 expression (6,8).”
BackgroundSelf-citationNivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447 · cited 2×
“The PD-1 axis blockers nivolumab (anti-PD-1) and atezolizumab (anti PD-L1) are additionally indicated for use as second-line therapy in patients with NSCLC regardless of tumor PD-L1 expression (6,8).”
BackgroundMutational landscape determines sensitivity to PD-1 blockade in non–small cell lung cancer
Rizvi, N. A., Hellmann, M. D., Snyder, A., Kvistborg, P., Makarov, V., Havel, J. J., Lee, W., Yuan, J., Wong, P., Ho, T. S., et al. (2015) · Science · doi:10.1126/science.aaa1348 · Cited by 7,802 · cited 2×
“This difference likely reflects the inclusion in our cohort of cases of metastatic lung cancer (as opposed to resectable cases included in the TCGA dataset) and of tumors that responded to ICIs (18).”
BackgroundMismatch repair deficiency predicts response of solid tumors to PD-1 blockade
Le, D. T., Durham, J. N., Smith, K. N., Wang, H., Bartlett, B. R., Aulakh, L. K., Lu, S., Kemberling, H., Wilt, C., Luber, B. S., et al. (2017) · Science · doi:10.1126/science.aan6733 · Cited by 6,645 · cited 2×
“Further underscoring the importance of these pathways for resistance to ICIs, defects in the IFN signaling pathway have also been found in melanomas with primary resistance to ipilimumab and pembrolizumab (23) and B2M mutations were recently found in metastatic colon cancers resistant to pembrolizumab (24).”
BackgroundHerbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449 · cited 1×
“Currently, the anti-PD-1 agent pembrolizumab is approved for use as first- and second- line therapy in patients with advanced NSCLCs whose tumors express PD-L1 using immunohistochemistry (IHC) (10,11).”
BackgroundSelf-citationPembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 3×
“The PD-1 receptor on cytotoxic T cells suppresses their activity when bound by its ligands PD-L1 or PD-L2 (2,3).”
BackgroundInfluentialRittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
Snyder, A., Makarov, V., Merghoub, T., Yuan, J., Zaretsky, J. M., Desrichard, A., Walsh, L. A., Postow, M. A., Wong, P., Ho, T. S., et al. (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1406498 · Cited by 4,286
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Zaretsky, J. M., Garcia-Diaz, A., Shin, D. S., Escuin-Ordinas, H., Hugo, W., Hu-Lieskovan, S., Torrejon, D. Y., Abril-Rodriguez, G., Sandoval, S., Barthly, L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1604958 · Cited by 3,237 · cited 1×
“In melanoma, acquired resistance to PD-1 inhibitors can be mediated by tumor cell-autonomous defects in interferon (IFN) signaling through JAK1/2 inactivating mutations; or defective HLA class I antigen processing through deleterious mutations in Beta-2 microglobulin [B2M] (22).”
BackgroundGenomic correlates of response to CTLA-4 blockade in metastatic melanoma
Van Allen, E. M., Miao, D., Schilling, B., Shukla, S. A., Blank, C., Zimmer, L., Sucker, A., Hillen, U., Geukes Foppen, M. H., Goldinger, S. M., et al. (2015) · Science · doi:10.1126/science.aad0095 · Cited by 2,839
Zou, W., Wolchok, J. D., & Chen, L. (2016) · Science Translational Medicine · doi:10.1126/scitranslmed.aad7118 · Cited by 2,400 · cited 3×
“The PD-1 receptor on cytotoxic T cells suppresses their activity when bound by its ligands PD-L1 or PD-L2 (2,3).”
BackgroundInfluentialKoyama, S., Akbay, E. A., Li, Y. Y., Herter-Sprie, G. S., Buczkowski, K. A., Richards, W. G., Gandhi, L., Redig, A. J., Rodig, S. J., Asahina, H., et al. (2016) · Nature Communications · doi:10.1038/ncomms10501 · Cited by 1,580 · cited 1×
“Indeed, upregulation of the immune inhibitory receptor TIM-3 on T-cells has been described to contribute to adaptive resistance to PD-1 blockade in mouse models and patient specimens (45).”
BackgroundT-Cell Transfer Therapy Targeting Mutant KRAS in Cancer
Tran, E., Robbins, P. F., Lu, Y.-C., Prickett, T. D., Gartner, J. J., Jia, L., Pasetto, A., Zheng, Z., Ray, S., Groh, E. M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609279 · Cited by 1,368
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Shin, D. S., Zaretsky, J. M., Escuin-Ordinas, H., Garcia-Diaz, A., Hu-Lieskovan, S., Kalbasi, A., Grasso, C. S., Hugo, W., Sandoval, S., Torrejon, D. Y., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-1223 · Cited by 1,337 · cited 2×
“Further underscoring the importance of these pathways for resistance to ICIs, defects in the IFN signaling pathway have also been found in melanomas with primary resistance to ipilimumab and pembrolizumab (23) and B2M mutations were recently found in metastatic colon cancers resistant to pembrolizumab (24).”
BackgroundLoss of IFN-γ pathway genes in tumor cells as a mechanism of resistance to anti-CTLA-4 therapy
Gao, J., Shi, L. Z., Zhao, H., Chen, J., Xiong, L., He, Q., Chen, T., Roszik, J., Bernatchez, C., Woodman, S. E., et al. (2016) · Cell · doi:10.1016/j.cell.2016.08.069 · Cited by 1,300 · cited 1×
“Since genetic defects in interferon pathway related genes have been associated with primary and acquired resistance to ICIs, we compiled a list of 101 IFN pathway-related genes (33) and queried them for mutations and copy number alterations in our cohort (excluding the hypermutator, case 17, that was examined separate…”
MethodDistinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas
Cancer Genome Atlas Research Network, Campbell, J. D., Alexandrov, A., Kim, J., Wala, J., Berger, A. H., Pedamallu, C. S., Shukla, S. A., Guo, G., Brooks, A. N., et al. (2016) · Nature Genetics · doi:10.1038/ng.3564 · Cited by 1,200 · cited 2×
“Of note, the median number of somatic mutations found in the pan-lung cancer analysis of TCGA data was 261, and 327 in a separate study of metastatic lung cancers (18,25).”
BackgroundGettinger, S. N., Horn, L., Gandhi, L., Spigel, D. R., Antonia, S. J., Rizvi, N. A., Powderly, J. D., Heist, R. S., Carvajal, R. D., Jackman, D. M., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.58.3708 · Cited by 1,177
Self-citationMutational signatures associated with tobacco smoking in human cancer
Alexandrov, L. B., Ju, Y. S., Haase, K., Van Loo, P., Martincorena, I., Nik-Zainal, S., Totoki, Y., Fujimoto, A., Nakagawa, H., Shibata, T., et al. (2016) · Science · doi:10.1126/science.aag0299 · Cited by 1,100 · cited 1×
“Our analysis revealed that in the majority of the tumor specimens the dominant mutation signatures were those associated with smoking, APOBEC mutations and to a lesser extent alkylating agents (26,27) (Supplementary Fig.”
BackgroundLynch, T. J., Bondarenko, I., Luft, A., Serwatowski, P., Barlesi, F., Chacko, R., Sebastian, M., Neal, J., Lu, H., Cuillerot, J.-M., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.4032 · Cited by 1,002
Peggs, K. S., Quezada, S. A., Chambers, C. A., Korman, A. J., & Allison, J. P. (2009) · Journal of Experimental Medicine · doi:10.1084/jem.20082492 · Cited by 967 · cited 1×
“Similarly, blockade of the T-cell inhibitory molecule CTLA-4 stimulates tumor antigen-specific immune responses by suppressing inhibitory signals on naïve T-cells and through elimination of regulatory T cells (4).”
BackgroundHellmann, M. D., Rizvi, N. A., Goldman, J. W., Gettinger, S. N., Borghaei, H., Brahmer, J. R., Ready, N. E., Gerber, D. E., Chow, L. Q., Juergens, R. A., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30624-6 · Cited by 962 · cited 1×
“However, early phase studies using the combination of CTLA-4 and PD-1 axis inhibitors in patients with advanced NSCLC have shown encouraging results (16,17).”
BackgroundSelf-citationThe future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Khalil, D. N., Smith, E. L., Brentjens, R. J., & Wolchok, J. D. (2016) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2016.25 · Cited by 929 · cited 1×
“Recent regulatory agency approvals of immune checkpoint inhibitors (ICIs) including programmed death 1 (PD-1), programmed death ligand 1 (PD-L1) and cytotoxic Tlymphocyte associated protein 4 (CTLA-4) antagonist antibodies for multiple advanced solid tumors have marked a new era of cancer therapeutics that will increa…”
BackgroundEvolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non–Small Cell Lung Cancer
Anagnostou, V., Smith, K. N., Forde, P. M., Niknafs, N., Bhattacharya, R., White, J., Zhang, T., Adleff, V., Phallen, J., Wali, N., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0828 · Cited by 896 · cited 1×
“In lung cancer, to date, neoantigen loss has been associated with acquired resistance to immune checkpoint blockade (21).”
BackgroundMelanoma Cell-Intrinsic PD-1 Receptor Functions Promote Tumor Growth
Kleffel, S., Posch, C., Barthel, S. R., Mueller, H., Schlapbach, C., Guenova, E., Elco, C. P., Lee, N., Juneja, V. R., Zhan, Q., et al. (2015) · Cell · doi:10.1016/j.cell.2015.08.052 · Cited by 639 · cited 1×
“Moreover, it is unclear what the consequences of a mutation in PDCD1, presumably on tumor cells, would be given that PD-1 is expected to function in T-cells although tumor cell autonomous functions have been reported (44).”
BackgroundAntonia, S., Goldberg, S. B., Balmanoukian, A., Chaft, J. E., Sanborn, R. E., Gupta, A., Narwal, R., Steele, K., Gu, Y., Karakunnel, J. J., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00544-6 · Cited by 602 · cited 1×
“However, early phase studies using the combination of CTLA-4 and PD-1 axis inhibitors in patients with advanced NSCLC have shown encouraging results (16,17).”
BackgroundSelf-citationRestifo, N. P., Marincola, F. M., Kawakami, Y., Taubenberger, J., Yannelli, J. R., & Rosenberg, S. A. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.2.100 · Cited by 533 · cited 1×
“It has additionally been implicated as a mechanism of resistance to immunotherapies including T-cell based therapies and vaccination in patients with advanced melanoma (29,40).”
BackgroundHLA antigen changes in malignant cells: epigenetic mechanisms and biologic significance
Campoli, M., & Ferrone, S. (2008) · Oncogene · doi:10.1038/onc.2008.273 · Cited by 404
Self-citationD'Urso, C. M., Wang, Z. G., Cao, Y., Tatake, R., Zeff, R. A., & Ferrone, S. (1991) · Journal of Clinical Investigation · doi:10.1172/jci114984 · Cited by 309
Self-citationXenome—a tool for classifying reads from xenograft samples
Conway, T., Wazny, J., Bromage, A., Tymms, M., Sooraj, D., Williams, E. D., & Beresford-Smith, B. (2012) · Bioinformatics · doi:10.1093/bioinformatics/bts236 · Cited by 276 · cited 1×
“For analysis of the PDXs, we used Xenome to classify the sequence reads and filter out the mouse sequence reads prior to alignment (46).”
MethodAcquired and intrinsic resistance in cancer immunotherapy
Kelderman, S., Schumacher, T. N. M., & Haanen, J. B. A. G. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2014.07.011 · Cited by 197 · cited 1×
“Since an important aspect of anti-tumor CD8 T cells is the ability to kill target tumor cells (32), we assessed the cytotoxicity of UNSCC680AJ tumor-specific CD8 T cells towards both the control (empty vector) and the B2m knockout UNSCC680AJ tumor cell lines.”
BackgroundLoss of Chromosome 8p Governs Tumor Progression and Drug Response by Altering Lipid Metabolism
Cai, Y., Crowther, J., Pastor, T., Abbasi Asbagh, L., Baietti, M. F., De Troyer, M., Vazquez, I., Talebi, A., Renzi, F., Dehairs, J., et al. (2016) · Cancer Cell · doi:10.1016/j.ccell.2016.04.003 · Cited by 190 · cited 1×
“One hypothesis is that while none of these events alone are sufficient to down-modulate antigen presentation, multiple hits together in the same pathway could have this effect similar to how hemizygous loss of multiple contiguous tumor suppressor genes can affect tumorigenesis (41,42).”
BackgroundGenetic evolution of T-cell resistance in the course of melanoma progression
Sucker, A., Zhao, F., Real, B., Heeke, C., Bielefeld, N., Maβen, S., Horn, S., Moll, I., Maltaner, R., Horn, P. A., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0567 · Cited by 171
Self-citationBenitez, R., Godelaine, D., Lopez‐Nevot, M. A., Brasseur, F., Jimenez, P., Marchand, M., Oliva, M. R., van Baren, N., Cabrera, T., Andry, G., et al. (1998) · Tissue Antigens · doi:10.1111/j.1399-0039.1998.tb03082.x · Cited by 149 · cited 1×
“It has additionally been implicated as a mechanism of resistance to immunotherapies including T-cell based therapies and vaccination in patients with advanced melanoma (29,40).”
BackgroundImmune escape of cancer cells with beta2‐microglobulin loss over the course of metastatic melanoma
del Campo, A. B., Kyte, J. A., Carretero, J., Zinchencko, S., Méndez, R., González‐Aseguinolaza, G., Ruiz‐Cabello, F., Aamdal, S., Gaudernack, G., Garrido, F., et al. (2014) · International Journal of Cancer · doi:10.1002/ijc.28338 · Cited by 147
A tumour suppressor network relying on the polyamine–hypusine axis
Scuoppo, C., Miething, C., Lindqvist, L., Reyes, J., Ruse, C., Appelmann, I., Yoon, S., Krasnitz, A., Teruya-Feldstein, J., Pappin, D., et al. (2012) · Nature · doi:10.1038/nature11126 · Cited by 141 · cited 1×
“One hypothesis is that while none of these events alone are sufficient to down-modulate antigen presentation, multiple hits together in the same pathway could have this effect similar to how hemizygous loss of multiple contiguous tumor suppressor genes can affect tumorigenesis (41,42).”
BackgroundChang, C., Campoli, M. R., & Ferrone, S. (2005) · Advances in cancer research · doi:10.1016/s0065-230x(05)93006-6 · Cited by 128
Self-citationZatloukal, P., Heo, D. S., Park, K., Kang, J., Butts, C., Bradford, D., Graziano, S., Huang, B., & Healey, D. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.8071 · Cited by 125 · cited 1×
“Anti-CTLA-4-directed therapies, like ipilimumab and tremelimumab have shown limited activity as single agents in lung cancer (14,15).”
BackgroundImplication of the β2-microglobulin gene in the generation of tumor escape phenotypes
Bernal, M., Ruiz‐Cabello, F., Concha, Á., Paschen, A., & Garrido, F. (2012) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-012-1321-6 · Cited by 114
Impact of pre-adapted HIV transmission
Carlson, J. M., Du, V. Y., Pfeifer, N., Bansal, A., Tan, V. Y. F., Power, K. A., Brumme, C. J., Kreimer, A., DeZiel, C. E., Fusi, N., et al. (2016) · Nature Medicine · doi:10.1038/nm.4100 · Cited by 112
Self-citationPereira, C., Gimenez-Xavier, P., Pros, E., Pajares, M. J., Moro, M., Gomez, A., Navarro, A., Condom, E., Moran, S., Gomez-Lopez, G., et al. (2017) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1946 · Cited by 109
Self-citationLoffredo, J. T., Burwitz, B. J., Rakasz, E. G., Spencer, S. P., Stephany, J. J., Giraldo‐Vela, J. P., Martin, S. R., Reed, J. S., Piaskowski, S. M., Furlott, J. R., et al. (2006) · Journal of Virology · doi:10.1128/jvi.01912-06 · Cited by 66 · cited 1×
“Target cell killing by tumor-specific CD8 T cells was determined using the following formula adapted from previous reports (50,51): Percentage of adjusted tumor cell death = (%7AAD+ CD45− cells with effector T cells – %7AAD+ CD45− cells without effector T cells).”
MethodAzpilikueta, A., Agorreta, J., Labiano, S., Perez‐Gracia, J. L., Sánchez-Paulete, A. R., Aznar, M. A., Ajona, D., Bazo, I. G., Larráyoz, M., Teijeira, Á., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2016.01.013 · Cited by 64 · cited 1×
“To further explore the role of B2M in mediating resistance to immune checkpoint inhibition, we examined the level of B2m protein in a murine carcinogen-induced lung cancer cell line, UN-SCC680AJ, which has been shown to be sensitive to anti-PD-1 therapy (31).”
BackgroundSelf-citationBrahmer, J. R., Horn, L., Jackman, D. M., Spigel, D. R., Antonia, S. J., Hellmann, M. D., Powderly, J. D., Heist, R. S., Sequist, L. V. D., Smith, D. C., et al. (2017) · Cancer Research · doi:10.1158/1538-7445.am2017-ct077 · Cited by 56
Self-citationPaschen, A., Arens, N., Sucker, A., Greulich-Bode, K. M., Fonsatti, E., Gloghini, A., Striegel, S., Schwinn, N., Carbone, A., Hildenbrand, R., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2174 · Cited by 36
Pereira, C. A., Giménez‐Xavier, P., Pros, E., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-1946-t · Cited by 34 · cited 1×
“Moreover, since genetic defects in antigen processing machinery genes have been found in ~5% of lung cancers and have been linked to reduced survival upon treatment with immune checkpoint inhibitors (25,43), the contribution of this pathway to primary resistance in lung cancer should also be considered.”
BackgroundBarlési, F., Steins, M. B., Horn, L., Ready, N., Felip, E., Borghaei, H., Spigel, D. R., Arrieta, O. G., Antonia, S., Fayette, J., et al. (2016) · Annals of Oncology · doi:10.1093/annonc/mdw383.15 · Cited by 22 · cited 1×
“Recently, a case of advanced melanoma with acquired resistance to the anti-PD-1 antibody, pembrolizumab, presumably mediated by B2M deficiency was reported (12).”
Background
Cited by
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
The biology and management of non-small cell lung cancer
Herbst, R. S., Morgensztern, D., & Boshoff, C. (2018) · Nature · doi:10.1038/nature25183 · Cited by 4,891
Self-citationThe evolving landscape of biomarkers for checkpoint inhibitor immunotherapy
Havel, J. J., Chowell, D., & Chan, T. A. (2019) · Nature Reviews Cancer · doi:10.1038/s41568-019-0116-x · Cited by 2,286
Bagchi, S., Yuan, R., & Engleman, E. G. (2021) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-042020-042741 · Cited by 2,189
Saxena, M., van der Burg, S. H., Melief, C. J. M., & Bhardwaj, N. (2021) · Nature reviews. Cancer · doi:10.1038/s41568-021-00346-0 · Cited by 1,581
Metadata
- Authors
- Gettinger, S., Choi, J., Hastings, K., Truini, A., Datar, I., Sowell, R., Wurtz, A., Dong, W., Cai, G., Melnick, M. A., Du, V. Y., Schlessinger, J., Goldberg, S. B., Chiang, A., Sanmamed, M. F., Melero, I., Agorreta, J., Montuenga, L. M., Lifton, R., Ferrone, S., Kavathas, P., Rimm, D. L., Kaech, S. M., Schalper, K., Herbst, R. S., & Politi, K.
- Affiliations
- Yale Cancer Center (US)
- Yale University (US)
- Clinica Universidad de Navarra (ES)
- Harvard University (US)
- Corresponding author
- Gettinger, Scott
- Politi, Katerina
- ORCID
- Gettinger, Scott
- Choi, Jungmin
- Hastings, Katherine
- Truini, Anna
- Sowell, Ryan
- Wurtz, Anna
- Dong, Weilai
- Cai, Guoping
- Melnick, Mary Ann
- Du, Victor Y.
- Schlessinger, Joseph
- Goldberg, Sarah B.
- Chiang, Anne
- Sanmamed, Miguel F.
- Melero, Ignacio
- Agorreta, Jackeline
- Montuenga, Luis M.
- Lifton, Richard
- Ferrone, Soldano
- Kavathas, Paula
- Rimm, David L.
- Kaech, Susan M.
- Schalper, Kurt
- Herbst, Roy S.
- Politi, Katerina
- Venue
- Cancer Discovery
- Published
- 2017-12-01
- Volume
- 7
- Issue
- 12
- Pages
- 1420-1435
- ISSN
- 2159-8274 (ISSN-L)
- 2159-8290
- PMC
- PMC5718941
- OpenAlex
- W2763186529
- Cited by
- 787
- References
- 53
- Citations by year
- 2026: 86 · 2025: 90 · 2024: 108 · 2023: 107 · 2022: 83 · 2021: 118 · 2020: 106 · 2019: 51 · 2018: 37
- FWCI
- 23.39
- Type
- journal article
- Language
- en
- Open access
- green
- europepmc.org
- Locations
- Cancer Discovery (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Funders
- National Institutes of Health (UL1TR001863)
- National Heart, Lung, and Blood Institute (T32HL007974)
- National Cancer Institute (F32CA210516, R01CA195720, P50CA196530, P30CA016359)
- National Center for Advancing Translational Sciences
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Keywords
- acquired resistance, immune checkpoint inhibitors, lung cancer, anti-PD-1 therapy, interferon signaling, tumor immune evasion, patient-derived xenografts, CRISPR knockout
- MeSH terms
- Humans, Lung Neoplasms, Histocompatibility Antigens Class I, Signal Transduction, Gene Expression Regulation, Neoplastic, Drug Resistance, Neoplasm
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.